MPDL3280A Shows Activity in Triple-Negative Breast Cancer

MPDL3280A Shows Activity in Triple-Negative Breast Cancer
In an updated analysis of a cohort of metastatic triple-negative breast cancer patients, it was demonstrated that MPDL3280A, a programmed death ligand 1 (PD-L1)–targeted immunotherapy, continues to be well-tolerated and to show signs of activity.
Read more on Cancer Network

Vaccinating Boys Against HPV Proves Cost-Effective
Vaccinating adolescent boys against the human papillomavirus (HPV) may be cost-effective in the prevention of oropharyngeal cancer, according to the results of a study published in Cancer. Using a cost-effectiveness analysis, Donna M. Graham, MB, BCh, …
Read more on Cancer Network

HPV Vaccine Can Protect Previously Exposed Patients
Vaccinating women between the ages of 18 and 25 against the human papillomavirus (HPV) resulted in protection at the three known sites of viral entry. The HPV 16/18 vaccine protected women from cervical, anal, and oral HPV infections that can lead to …
Read more on Cancer Network

This entry was posted in Searchmedica and tagged , , , , , . Bookmark the permalink.